Effect of Methotrexate on Rheumatoid Factor on Patients With Rheumatoid Arthritis. Cumana, Venezuela, 2006

EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE; 99Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS

“…Despite RA affecting approximately 1% of the world's population, 1–3 our understanding of the underlying pathophysiology remains incomplete and the optimal strategy for controlling disease in patients with RA in many cases remains unclear 4 . Although the benefits of early treatment with non‐steroidal anti‐inflammatory drugs (NSAIDs) and disease‐modifying antirheumatic drugs (DMARDs) are indisputable, 5–11 long‐term systemic therapy fails in a number of cases and the use of these agents can be limited by gastrointestinal side‐effects. Biological agents, such as anti‐tumour necrosis factor (TNF) antibody, have shown marked improvement in outcomes in RA patients; 12–15 however, the use of such treatments may carry an increased risk of other diseases, such as tuberculosis, systemic lupus erythematosus and malignancy 16 .…”